Kairos Pharma KAPA 深 滬
已收盤 07-31 16:00:00 美东时间
0.3061
+0.006
+2.07%
華盛通- 最 高0.3299
- 今 開0.3192
- 成交量 242.04万股
- 最 低 0.2905
- 昨 收 0.2999
- 總市值 655.40万
- 52周最高 2.11
- 市盈率 靜 --
- 換手率 11.30%
- 52周最低 0.2695
- 委 比 0.00%
- 總股本 2141.12万
- 歷史最高 4.00
- 量 比 2.99
- 振 幅 13.14%
- 歷史最低 0.2695
- 每 手 1
- 風險率 0.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kairos Pharma Partners With Bayer To Mull ENV-105 Inhibitor In Combination With Bayer’s XOFIGO
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in...
07-22 20:37
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?
Kairos Pharma, Ltd. (NYSE:KAPA) shares surged 22.64% to $0.39 in after-hours trading on Wednesday following the company’s announcement of positive interim safety data for its lead cancer drug candidate. The stock had closed down 6.47% at $0.32 during regular trading. Safety Data Fuels Investor Optim...
07-16 14:51
Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate
Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the same
04-01 06:37
Kairos Pharma Signs Deal To Acquire Two Experimental Lung Cancer Drug Candidates, Financial Terms Undisclosed
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn
02-26 20:14
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.
2025-11-04 22:30
Kairos Pharma Approves RSUs and Cash Bonuses
Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On October 8, 2025,...
2025-10-16 04:28
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
2025-09-22 18:44
